HK Stock Market Move | TYK MEDICINES-B (02410) rose more than 7% with an annual research and development cost of approximately 2.44 billion yuan. It will showcase five innovative drug research results at the AACR annual meeting.

TYK MEDICINES-B(02410) surged more than 7%, as of the time of reporting, it increased by 7.07%, reaching 10.9 Hong Kong dollars, with a trading volume of 30,537.2 million Hong Kong dollars. On the news front, on March 31, TYK MEDICINES-B released its annual performance for the year ending December 31, 2025, with research and development costs of approximately 244 million yuan, an increase of 3.7% year-on-year; other income and gains of 37.609 million yuan, an increase of 23.14% year-on-year. During the reporting period, other income and gains mainly included government subsidies related to income, government subsidies related to interest-free financing, and income from the sale of a subsidiary company. Of note, TYK MEDICINES-B announced that the company will present the research progress and achievements of five innovative drug projects in development at the 2026 American Association for Cancer Research (AACR) annual meeting, including TY-0609 (CDK4 inhibitor), TY-2699a (CDK7 inhibitor), TY-2719 (EGFR/FAK (PROTAC) inhibitor), PI3K (PI3K inhibitor), and TY-1054 (YAP-TEAD inhibitor). These five projects being showcased are all independently developed anti-tumor small molecule innovative candidate drugs by the company. The AACR annual meeting will be held in San Diego, United States from April 17 to 22, 2026, with the company's poster presentations scheduled for April 19 to April 21.